TENSIVE CONTROLS, INC.
Biotech · Private
A melanocortin antagonist peptide therapeutic (TCMCB07) with extended half-life to treat cachexia-anorexia syndrome
- Grants
- $2.6M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 4 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201320142015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Agriculture · Development Of Anti-microbial Peptide Therapeutics | $99,478 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Cancer Cachexia Therapeutic | $204,519 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Cancer Cachexia Therapeutic | $898,017 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Cancer Cachexia Therapeutic | $1,415,204 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2239 | Forecast Bio, Inc. | — | $2.4M |
| 2240 | Monocacy Therapeutics Inc. | — | $389K |
| 2241 | POWERHOUSE PROTEOMIC SYSTEMS, LLC | — | — |
| 2242 | TENSIVE CONTROLS, INC. | — | — |
| 2243 | Acelyrin | — | — |
| 2244 | Cour Pharmaceutical | — | — |
| 2245 | AVEXEGEN THERAPEUTICS INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Anti-microbial Peptidesgranted
- Angiotensin (1-7) Analogs And Methods Relating Theretogranted
- Anti-microbial Peptidesgranted
- Melanocortin Analogs Having Enhanced Activity And Transportapplication
- Melanocortin Analogs Having Enhanced Activity And Transportgranted
- Stabilized Melanocortin Ligandsapplication
- Angiotensin (1-7) Analogs And Methods Relating Theretoapplication
- Anti-microbial Peptidesapplication
- Anti-microbial Peptidesapplication
- Melanocortin Analogs Having Enhanced Activity And Transportapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.